General Overview - The company has established a financial derivatives trading management system to regulate its trading activities and control associated risks, in compliance with relevant laws and regulations [1][2][3] Financial Derivatives Definition - Financial derivatives include products such as futures, options, forwards, and swaps, which can be based on various underlying assets including securities, indices, interest rates, exchange rates, currencies, and commodities [1] Applicability - The management system applies to the company and its wholly-owned and controlling subsidiaries, prohibiting them from engaging in financial derivatives trading without the company's consent [1][2] Trading Counterparties - The company is only allowed to trade with financial institutions that have been approved by regulatory authorities, ensuring that transactions are conducted with qualified entities [2] Trading Accounts - The company must establish dedicated financial derivatives trading accounts in its name and is prohibited from using third-party accounts for trading [2] Capital Requirements - The company must have sufficient self-owned funds that match the margin requirements for financial derivatives trading and must strictly control the scale of trading to avoid impacting normal operations [2][3] Management Structure - A financial derivatives trading working group, led by the chairman and including key executives, is responsible for the implementation and management of trading activities [2][3] Risk Assessment - The finance department is tasked with evaluating trading risks and preparing feasibility analysis reports, which must be submitted to the board for review [3][4] Audit and Supervision - The audit department oversees the trading activities, conducting pre-approval, ongoing supervision, and post-audit to ensure compliance and proper fund usage [3][4] Approval Process - Major trading plans and limits must be approved by the board and, in certain cases, by the shareholders, especially when the trading involves significant amounts relative to the company's net profit or net assets [4][5] Authorization Management - The company implements an authorization management system for trading operations, requiring written authorization for any trading activities [5][6] Risk Control Measures - The company must clearly define roles and responsibilities within the trading team and ensure that incompatible functions are separated to maintain checks and balances [6][7] Market Analysis - Prior to engaging in trading, the company should conduct market comparisons and select financial derivatives that align with its business needs and risk tolerance [6][7] Ongoing Management - The finance department is responsible for tracking market prices and assessing the risk exposure of invested derivatives, reporting any significant changes to the board [7][8] Disclosure Requirements - The company must disclose any confirmed gains or losses from derivatives trading that exceed 10% of the most recent audited net profit [8] Record Keeping - All trading documentation and authorization records must be properly archived by the finance department and the board [8][9] Confidentiality - Employees involved in derivatives trading must adhere to confidentiality protocols to protect sensitive information related to trading activities [8][9] Implementation Date - The management system will take effect upon approval by the company's board [9]

浙江大自然户外用品股份有限公司 2024 年年度股东大会会议资料 证券代码：605080 证券简称：浙江自然 浙江大自然户外用品股份有限公司 会议资料 浙江大自然户外用品股份有限公司 2024 年 年度股东大会会议资料 浙江大自然户外用品股份有限公司 2024 年年度股东大会会议资料 浙江大自然户外用品股份有限公司 各位股东及股东代理人： 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东会规则》和公司《股东大会议事规则》 等有关规定，特制定本会议须知，请参会人员认真阅读。 一、公司负责本次股东大会的议程安排和会务工作，出席会议人员应当听从公 司工作人员安排，共同维护好会议秩序。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签到 手续，并按规定出示证券账户卡、身份证明文件或营业执照/注册证书复印件（加盖 公章）、授权委托书等，上述登记材料均需提供复印件一份，个人登记材料复印件 须个人签字，法定代表人证明文件复印件须加盖公司公章，经验证后方可出席会议。 会议开始后, 由会议主持人宣布现场出席会议的股东人数及其所持有表决权的 股份总数 ...

江苏共创人造草坪股份有限公司 会议资料 二〇二五年五月 江苏共创人造草坪股份有限公司 2024 年年度股东大会会议资料 一、2024 年年度股东大会会议须知 非累积投票议案： 江苏共创人造草坪股份有限公司 2024 年年度股东大会会议资料 江苏共创人造草坪股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的顺 利进行，根据《江苏共创人造草坪股份有限公司章程》（以下简称《公司章程》）、《江 苏共创人造草坪股份有限公司股东大会议事规则》及相关法律法规的规定，特制定本须知。 一、董事会以维护股东的合法权益、确保大会正常秩序和议事效率为原则，认真履行 《公司章程》中规定的职责。 二、本公司证券部具体负责大会有关程序方面的事宜。 三、股权登记日登记在册的所有股东或其代理人均有权出席股东大会。出席会议的股 东（或股东代表）必须在会议召开前按此次会议召开通知中载明的要求向公司证券部办理 签到登记手续。 席的，凭代理人的身份证原件、授权委托书原件（格式详见此次会议召开通知附件，下同）、 委托人证券账户卡及委托人身份证复印件办理登记。 证明书（加盖公章）或法人单位出具的授权委托书原件（加盖公章 ...

Group 1 - The company will hold its 2024 Annual General Meeting on May 19, 2025, to discuss various proposals, including the use of idle funds for cash management [1][3] - The meeting will adopt a combination of on-site and online voting methods, allowing shareholders to exercise their voting rights through the Shanghai Stock Exchange's online voting system [2][3] - A total of 16 proposals will be reviewed during the meeting, with specific proposals requiring a two-thirds majority for special resolutions and a simple majority for ordinary resolutions [3][4] Group 2 - The company reported a net profit attributable to shareholders of -38,625,401.12 RMB for the year 2024, leading to a proposal not to distribute profits or increase capital reserves [15][16] - The company plans to use up to 600 million RMB of idle self-owned funds for cash management in non-related financial institutions, aiming to improve fund efficiency and returns [24][25] - The company intends to apply for a comprehensive credit limit of up to 1,969 million RMB from non-related financial institutions for its operational needs in 2025 [20][21] Group 3 - The company will engage in financial derivative trading in 2025 to hedge against exchange rate risks related to its export business, with a maximum trading amount of 8 million USD [21][22] - The board of directors will continue to strengthen investor relations management and ensure compliance with information disclosure regulations [10][11] - The company’s audit committee and other committees have been actively involved in overseeing financial reporting and compliance, ensuring the company operates within legal frameworks [7][9]

经审议，公司监事会及全体监事认为：为规范公司的证券投资行为，建立完善有序的投资决策管理机 制，有效防范投资风险，强化风险控制，保证公司资金、财产安全，维护投资者和公司合法权益，根据 《公司法》《证券法》《上海证券交易所股票上市规则（主板）》等有关规定，并结合《公司章程》， 同意制定《公司证券投资及金融衍生品交易管理制度（2025年4月）》。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《辰欣药业股份有限公司证券 投资及金融衍生品交易管理制度（2025年4月）》。 表决结果：3票同意，0票反对，0票弃权。 12、审议通过《公司关于提请股东大会授权董事会决定2025年中期分红方案的议案》 11、审议通过《关于制定＜公司证券投资及金融衍生品交易管理制度＞的议案》 根据《中华人民共和国公司法》《上市公司监管指引第3号一一上市公司现金分红》《公司章程》的有 关规定，结合公司实际情况，公司拟增加分红频次，由董事会提请股东会授权董事会制定2025年中期分 红方案。公司在2025年度进行中期分红的，应同时满足下列条件：1）公司当期归属于上市公司股东的 净利润为正，且累计未分配利润亦为正数；2 ...

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in its announcements [7][22]. - The board of directors and senior management confirm the truthfulness of the quarterly report and assume legal responsibility for any misrepresentation [2][3]. - The first quarter report for 2025 has not been audited [6]. Group 2 - The profit distribution plan for 2024 proposes a cash dividend of 3.00 yuan per 10 shares, totaling approximately 24.90 million yuan, which is 39.06% of the net profit attributable to shareholders [9][10]. - The total distributable profit for 2024 is 34.85 million yuan, after accounting for legal reserves and previous undistributed profits [9][10]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [12][13]. Group 3 - The company plans to engage in financial derivatives trading in 2025 to hedge against currency and interest rate risks, with a maximum contract value of 250 million yuan [23][25]. - The board has approved the financial derivatives trading proposal, which aims to use self-owned funds for hedging purposes [26]. - The company will implement risk control measures to mitigate potential market, liquidity, and legal risks associated with financial derivatives trading [27][28]. Group 4 - The company has outlined expected related party transactions for 2025, including procurement and service agreements, with total amounts not exceeding 30 million yuan [32][38]. - The related party transactions are conducted at market prices and are not expected to significantly impact the company's financial status or independence [38][41]. - The independent directors have reviewed and approved the related party transactions before submission to the board [39].

Core Points - The company held the 19th meeting of the sixth Supervisory Board on March 26, 2025, where several key resolutions were passed regarding the 2024 annual reports and financial matters [1][2][3]. Group 1: Supervisory Board Resolutions - The Supervisory Board approved the 2024 Annual Work Report, which will be submitted to the 2024 Annual General Meeting for review [1]. - The 2024 Financial Settlement Report was also approved, reflecting the company's actual operating conditions [1]. - The company will recognize an asset impairment provision totaling 701.48 million yuan for 2024, which includes previously disclosed impairments [1]. - The 2024 Annual Report and its summary were approved, confirming that the reports accurately reflect the company's situation [1]. - The profit distribution plan for 2024 was approved, with a net profit of approximately 2.67 billion yuan attributable to shareholders [1]. Group 2: Financial and Operational Plans - The company plans to apply for a comprehensive credit limit of up to 38 billion yuan for 2025 to support its operations [6]. - A proposal to use up to 5 billion yuan of self-owned funds for entrusted wealth management in 2025 was approved [7]. - The company will engage in financial derivatives trading with a total limit of up to 6 billion USD in 2025 to manage foreign exchange risks [9]. - The company will provide guarantees for certain subsidiaries with a total limit of up to 4.03 billion yuan [12]. - The company plans to support its subsidiary, Goertek Optical Technology, with financial assistance of up to 1 billion yuan [15]. Group 3: Internal Control and Governance - The company conducted a self-evaluation of its internal control for 2024, which was approved by the Supervisory Board [6]. - The internal control system was deemed adequate and compliant with relevant laws and regulations [6]. - The company updated its internal control system to enhance management and risk prevention capabilities [19].